Clinical Trial Update: Change in Quality of Life After Addition of Weekly 40 mg Pegvisomant/Placebo in Controlled Acromegalic Patients [Phase 4]

View source ↗

Summary

This Phase 4 clinical trial update reports changes in quality of life after addition of weekly 40 mg pegvisomant versus placebo in controlled acromegalic patien…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acromegaly

Drugs mentioned

• Pegvisomant (pegvisomant)

Snippet

Sponsor: Erasmus Medical Center | Conditions: Quality of Life, Acromegaly | Phase 4 | Status: COMPLETED